Clarivate Epidemiology’s coverage of hepatocellular carcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence…
Clarivate Epidemiology’s coverage of hepatocellular carcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence…
Clarivate Epidemiology’s coverage of hepatocellular carcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence…
Clarivate Epidemiology’s coverage of hepatocellular carcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence…
UNDERSTAND THE TOTAL MARKET SIZE AND TREATMENT OPPORTUNITIES FOR BIOMARKERS The development of biomarker-driven therapies continues to be a major trend in oncology. As biomarkers are often…
Clarivate Epidemiology’s coverage of ovarian cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of renal…
Non-small-cell lung cancer (NSCLC), a dynamic oncology indication with high unmet need, remains a key area of focus for drug developers. NSCLC is defined by driver mutations, and treatment is…
For the past decade, Erbitux-based regimens have been the mainstay of treatment for recurrent or metastatic non-nasopharyngeal squamous cell carcinoma of the head and neck (SCCHN), but the launches…
Building on the success of the PD-1 inhibitor Opdivo (Bristol Myers Squibb / Ono Pharmaceutical) in the recurrent renal cell carcinoma setting, combination regimens, including Opdivo plus Yervoy,…
Treatment for recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) has remained relatively unchanged in the past ten years, and Erbitux-based regimens continue to be the…
DRG Epidemiology’s coverage of endometrial cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Hepatocellular carcinoma is a primary malignancy of the liver that commonly arises from liver cirrhosis. Nexavar (Bayer HealthCare / Amgen / Onyx) was the only drug approved for advanced disease…
Clarivate Epidemiology’s coverage of hepatocellular carcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence…
NASH is an increasingly prevalent disease characterized by excess lipid (steatosis) in the liver, resulting in inflammation and eventually liver fibrosis. Ensuing complications can include liver…
Endometrial cancer is the sixth most common cancer in women worldwide. While the majority of patients present with early stage disease at diagnosis, efficacious therapeutic options for advanced or…